GlassScriptPhysician profile
Chitra D Rajagopal
NPI 1467544312
$88,683.72
in general payments reported to CMS, 2019-2025
51 companies · $1,863 in 2025
The $1,863 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $25K · 2021: $5,936 · 2022: $9,744 · 2023: $27K · 2024: $4,400 · 2025: $1,863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $16K · Consulting Fee: $8,375 · Food and Beverage: $4,421 · Travel and Lodging: $3,867 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,000 · Education: $126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $15,642.00 |
| Consulting Fee | $8,375.00 |
| Food and Beverage | $4,420.73 |
| Travel and Lodging | $3,867.24 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,000.00 |
| Education | $125.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cornerstone Specialty Network LLC | $31,933.27 | 2019-2023 | |
| Daiichi Sankyo INC. | $27,030.90 | 2020-2025 | Enhertu, Enhertu, Injectafer |
| Astrazeneca Pharmaceuticals LP | $8,593.55 | 2019-2024 | Calquence |
| Bayer Healthcare Pharmaceuticals INC. | $6,302.83 | 2019-2020 | |
| Exelixis INC. | $2,565.00 | 2019 | |
| Beigene USA, INC. | $2,400.00 | 2022-2023 | Brukinsa |
| Coherus Oncology, INC. | $1,088.00 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $1,050.00 | 2022 | |
| Athenex Pharmaceutical Division, LLC | $1,000.00 | 2021 | |
| Avyxa Pharma, LLC | $1,000.00 | 2025 | |
| Seagen INC. | $927.94 | 2021-2023 | |
| Pfizer INC. | $499.11 | 2019-2025 | |
| Glaxosmithkline, LLC. | $418.96 | 2022-2025 | Zejula, Jemperli, Ojjaara |
| Genzyme Corporation | $416.06 | 2022-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $380.86 | 2021-2023 | Imbruvica, Epkinly |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $362.72 | 2021-2025 | Keytruda |
| Astellas Pharma US INC | $234.16 | 2022-2025 | Cresemba, Vyloy, Padcev |
| Celgene Corporation | $233.30 | 2020-2025 | Reblozyl, Pomalyst |
| Janssen Biotech, INC. | $204.88 | 2022-2024 | Darzalex, Tecvayli, Talvey |
| Abbvie INC. | $175.56 | 2024-2025 | |
| Gilead Sciences, INC. | $171.78 | 2021-2025 | Trodelvy |
| Ge Healthcare | $138.65 | 2021-2022 | |
| Array Biopharma INC | $124.72 | 2021-2025 | Lorbrena, Braftovi, Mektovi |
| Puma Biotechnology, INC. | $119.87 | 2019-2025 | |
| Amgen INC. | $118.58 | 2022-2023 | Kyprolis, Blincyto |
| Novartis Pharmaceuticals Corporation | $112.59 | 2019-2023 | |
| Genentech USA, INC. | $101.29 | 2019-2023 | Phesgo |
| Sobi, INC | $88.06 | 2022-2023 | |
| Cti Biopharma Corp. | $85.13 | 2022 | |
| Stemline Therapeutics INC. | $83.57 | 2023-2025 | Orserdu |
| E.R. Squibb & Sons, L.L.C. | $77.26 | 2024 | Opdivo, Augtyro |
| Tersera Therapeutics LLC | $76.82 | 2022-2024 | Xermelo |
| Karyopharm Therapeutics INC. | $61.68 | 2025 | Xpovio |
| Janssen Pharmaceuticals, INC | $57.49 | 2021-2023 | Xarelto |
| Rigel Pharmaceuticals, INC. | $48.17 | 2022-2025 | Gavreto, Rezlidhia, Tavalisse |
| Eisai INC. | $47.11 | 2023-2025 | |
| Servier Pharmaceuticals LLC | $37.52 | 2022-2024 | |
| Immunocore Limited | $32.43 | 2025 | Kimmtrak |
| Caris Mpi, INC. | $30.30 | 2025 | Mi Cancer Seek |
| Legend Biotech USA INC. | $25.72 | 2024 | Carvykti |
| Beone Medicines USA, INC. | $25.48 | 2025 | Brukinsa |
| Emd Serono, INC. | $24.67 | 2025 | |
| Fennec Pharmaceuticals, INC. | $24.60 | 2025 | Fyarro |
| Incyte Corporation | $24.04 | 2021 | |
| Tg Therapeutics, INC. | $23.28 | 2021 | |
| Menarini Silicon Biosystems, INC. | $20.96 | 2024 | |
| Iovance Biotherapeutics, INC. | $20.80 | 2024 | Amtagvi |
| Tactile Systems Technology INC | $17.31 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $16.78 | 2023 | Sancuso |
| Cycle Pharmaceuticals INC | $16.75 | 2025 | Phyrago |
| Foundation Medicine, INC. | $13.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$54,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chitra Rajagopal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.